Global Neuroprotective Agents Market Size, Trends & Analysis - Forecasts To 2026 By Drug (Cholinesterase Inhibitors, Anti-inflammatory & Anti-apoptotic Agents, NMDA Receptor Antagonists, Neurotropic Factors, Mitochondrial Dysfunction Regulators, Free Radical Trappers, Anti-Excitotoxic Agents, Others), By Indication (Alzheimers Disease, Multiple Sclerosis, Parkinsons Disease, Huntingtons Disease, Neuropathies, Brain Injury, Others), By Region (North America, Europe, Asia Pacific, MEA, CSA), Vendor Landscape, End User Landscape and Company Market Share Analysis & Competitor Analysis
Neuroprotective Agents Market Insights
The global neuroprotective agents market is estimated to witness a significant CAGR during the forecast period (2020-2026). Growing incidence and prevalence of neurodegenerative diseases along with rise in stroke and traumatic central nervous system injuries are some of the major factors expected to drive the market growth during the forecast period. Moreover, rising demand for the product for various purposes in hospitals, medical facilities, and nursing homes is one of the significant factors driving market growth. Neuroprotective agents have potential in reducing stroke damage. Neuroprotective agents in clinical pipelines include small-molecule drugs, therapeutic monoclonal antibodies, gene and cell therapies, and other agents. Neuroprotection or prevention of neuronal loss is a process that is mediated by various cellular pathways. The most common conditions associated with nervous system involvement are trauma, shock, stroke, sepsis, traumatic brain injury (TBI) and ruptured brain aneurys and their increasing prevalence is the major driver for the market growth. However, insufficient clinical research, and high costs in developing the product are some of the factors likely to hamper the market growth.
Neuroprotective Agents Market Size: By Drug
Based on drug, the market is segmented into cholinesterase inhibitors, anti-inflammatory & anti-apoptotic agents, NMDA receptor antagonists, neurotrophic factors, mitochondrial dysfunction regulators, free radical trappers, and anti-excitotoxic agents, among others. The cholinesterase inhibitors segment is expected to grow at a high CAGR during the forecast period. Cholinesterase Inhibitors are prescribed to individuals with dementia caused by Alzheimers disease. Furthermore, NMDA receptors are expected to hold the largest market share during the forecast period. NMDA receptors antagonists were the first class of therapeutic agents for acute stroke. They used modern principles of clinical trial design, developed from laboratory to testing in humans, and had early treatment.
Neuroprotective Agents Market Size: By Indication
Based on the indication, the market is segmented into Alzheimers disease, multiple sclerosis, Parkinsons disease, Huntingtons disease, neuropathies, and brain injury, among others. There has been an evolution of cotinine as neuroprotective agents and it improves information processing, attention, and memory-related task performance that have relevance to Alzheimers disease. Minocycline, creatine, and rasagiline are the most promising agents for neuroprotection in Parkinsons disease and all three are now in Phase III trials and market share shall increase in the forecast period due to new drug discovery and clinical trials.
Neuroprotective Agents Market Size: By Region
Based on region, the market is segmented into North America, Europe, Asia-Pacific, CSA, and Middle East and Africa. North America is expected to hold the largest market share during the forecast period. According to the research conducted, approximately 60,000 U.S. population is diagnosed with Parkinsons disease every year. Growing demand for neuroprotective drugs and investment in research and development activities is expected to propel the market growth in the region. Asia-Pacific region is expected to grow at a high CAGR during the forecast period with increasing investment in drug discovery and emergence of key players, and growing preventive health care measures.
Neuroprotective Agents Market Share & Competitor Analysis
Some of the key players operating in the neuroprotective agents market include: Eisai Inc. Merck, Serono S.A., Novartis AG, GlaxoSmithKline Plc, Bayer Healthcare, Genervon Biopharmaceuticals, NeuroVive Pharmaceutical, Teva Pharmaceutical Industries Ltd., Ceregene, BHRPharma LLC, Allon therapeutics, Inc., Neuren Pharmaceuticals, and Bionure Inc., among others.
Please note: This is not an exhaustive list of companies profiled in the report.
In May 2020, GlaxoSmithKline Plc entered into partnership with Samsung Biologics to manufacture and supply GSKs innovative biopharmaceutical therapies worldwide
In May 2020, Bayer entered into collaboration with ArcherDX to develop next-generation sequencing (NGS)-based companion diagnostic (CDx) for precision oncology treatment Vitrakvi
Neuroprotective Agents Market: By Drug
Neuroprotective Agents Market: By Indication
Neuroprotective Agents Market: By Region
The global Neuroprotective Agents Market has been studied from the year 2017 till 2026. However, the CAGR provided in the report is from the year 2018 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply side analysis for the Neuroprotective Agents Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the companies and customer analytics.
80% of our clients seek made-to-order reports. How do you want us to tailor yours?